CAIRDAC Appointed Raymond W. Cohen as Chairman
The leadless pacemaker developer tapped the veteran executive to guide its European clinical strategy.
Updated on Sept. 24, 2026 in Healthcare
CAIRDAC has named Raymond W. Cohen as chairman of its board of directors. The appointment follows Cohen's recent leadership in multiple high-value medtech exits.
Why it matters
Cohen brings a track record of scaling niche medtech firms toward significant acquisitions, a pivot point for CAIRDAC as it advances its self-powered cardiac device toward first-in-human studies.
Cohen recently oversaw exits totaling over $1.1 billion across two firms in 2025, operating within a global pacemaker market valued at approximately $5.5 billion.
The players
CAIRDAC
An Antony, France-based medical technology company developing self-powered, leadless cardiac pacemakers.
Raymond W. Cohen
A veteran medtech executive known for leading companies through clinical scaling and multi-hundred-million-dollar acquisition exits.
Boston Scientific
A global medical device manufacturer that acquires specialized medtech firms to expand its cardiac and neuromodulation portfolios.
The details
CAIRDAC focuses on its proprietary ALPS technology, which utilizes a frequency-tuned piezoelectric harvester to convert heart movement into electrical power for leadless pacemakers. With preclinical results recently published in a 2026 Europace abstract, the company is now navigating the regulatory path toward CE marking in Europe. This board-level appointment positions the firm to leverage Cohen's experience in steering companies through clinical development and eventual trade sales.
Timeline
September 24, 2026: CAIRDAC appointed Raymond W. Cohen as chairman.
2026: Preclinical results were reported in a Europace abstract.
2025: Cohen led the sales of SoniVie and Nalu Medical.
Late 2024: Boston Scientific acquired Axonics for $3.7 billion.
Market Landscape
The appointment follows the trend established by the 2024 acquisition of Axonics, Inc. by Boston Scientific as firms seek leadership with proven track records in high-value medtech trade sales. This move underscores the high premium currently placed on specialized cardiac technologies within the $5.5 billion pacemaker sector.
Operators should monitor CAIRDAC's clinical progress as a signal for the commercial viability of piezoelectric-based leadless devices. The company's focus on European CE marking should be tracked as a benchmark for potential U.S. pivotal study requirements.
The takeaway
The hiring of a serial exit-focused chairman signals that CAIRDAC is prioritizing a clear path to acquisition over independent long-term commercialization. Market participants should monitor the firm's progress in securing CE marking, as this remains the primary regulatory hurdle for its European market entry.
Further reading
For more on industry-leading moves, see the latest updates in Healthcare.
